CA2199642C - Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin - Google Patents
Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin Download PDFInfo
- Publication number
- CA2199642C CA2199642C CA002199642A CA2199642A CA2199642C CA 2199642 C CA2199642 C CA 2199642C CA 002199642 A CA002199642 A CA 002199642A CA 2199642 A CA2199642 A CA 2199642A CA 2199642 C CA2199642 C CA 2199642C
- Authority
- CA
- Canada
- Prior art keywords
- oligosaccharide
- aspirin
- sulpho
- alpha
- sulphoamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Abstract
The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty.
The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.
The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.
Description
"COMPOSITIONS CONTAINING AN ASSOCIATION OF ASPIRIN AND
AN ANTI-Xa OLIGOSACCHARIDE AND USE OF AN ANTI-Xa OLIGOSACCHARIDE OPTIONALLY IN COM3INATION WITH ASPIRIN"
The subject of the present inventlon is the use of synthetic oligosaccharides with factor Xa inhibiting activity which act via antithrombin III, alone or in combination with aspirin, in the treatment of thromboembolic diseases which occur during or after a percutaneous transluminal angioplasty (PTCA).
Pharmaceutical compositions containing the combination of the active ingredients oligosaccharides and aspirin are also part of the invention.
The active ingredients which constitute the combination are present in the free state or in the form of one of their pharmacologically acceptable salts.
During the last decade, a wide interest has been shown in the study of the role played by platelets in the development of the thromboembolic diseases associated with arteriosclerosis (myocardial infarc-tion, angina, cerebral vascular accident, arterial diseases of the lower limbs and the li~e). Moreover, the well-established role of the blood coagulation process in arterial thrombosis has allowed the development of numerous medicaments which inhibit the various coagulation enzymes. The discovery of the essential role of thrombin and of factor Xa in the thrombotic process has led to the use of anticoagulants being proposed in the prevention and treatment of arterial thrombosis.
Among the available anticoagulants, heparin is the preferred medicament in the prevention and treatment of thromboembollc diseases.
~eparin catalyses, especially via antithrombin III (AT III), the inhibition of two enzymes which are la involved in the blood coagulation cascade, namely factor Xa and factor IIa (or thrombin). The relative importance of these two activities in the overall activity of heparin remains unknown. Low molecular weight heparin (LMWH) preparations contain chains formed of 4 to 30 monosaccharides which act like property of being more selective for factor Xa than thrombin. Despite this different biological activity profile, low molecular weight heparin has an antithrombotic effect as has been demonstrated in studies on animals and on patients suffering from thromboembolic diseases or exhibiting risks of formation of a thrombus (Hirsch J. et al, J. Thromb.
Hemost., 1987, Leuven, Belgium Leuven University Press, 325-348).
Unlike heparin and the LMWHs, some synthetic oligosaccharides, especially those described in EP
84999, have the property of selectively inhibiting factor Xa via antithrombin III but do not possess any activity on thrombin.
lS These synthetic oligosaccharides corresponding to the antithrombin binding domain (ABD) of heparin are known and manifest an antithrombotic activity in venous thrombosis. These compounds are described in EP 529715 and EP 621282 The efficacy of these oligosaccharides in the treatment of thromboembolic diseases occurring during or after percutaneous transluminal angioplasty was not very likely because of their incapacity to inhibit thrombin which is the mechanism involved in the thromboses resulting from a PTCA.
Indeed, it has long been known in the literature that thrombin plays a key role in arterial thrombosis and this is again confirmed by recent experiments (L. A. Harker, Blood, 1991, 77, 1006-1012). Thrombin inhibitors therefore constitute aneffective means for preventing and combating this type of thrombosis after PTCA.
It has been observed, by comparing the efficacy of heparin with those of direct thrombin inhibitors (a direct inhibitor is an inhibitor which inhibits thrombin without requiring AT III as intermediate), that the latter are a lot more effective than heparin for preventing and treating arterial thrombosis (Arteriosclerosis and thrombosis, 1992, 12, 879-885. J.
Am. Coll. Cardiol., 1994, 23, 993-1003). The probable reason for this lack of efficacy is that the heparin/AT
III complex cannot, for reasons to do with stearic hindrance, inhibit thrombin in a platelet-rich thrombus as is a platelet thrombus.
The weak heparin activity, compared to the direct inhibitors, is therefore linked to its need to use AT III.
A compound which, on the one hand, acts itself via AT III as intermediate, and, on the other hand, does not inhibit thrombin would therefore be expected to be ineffective in the treatment of arterial thromboses after percutaneous transluminal angioplasty.
It has now been found, according to the present invention, quite surprisingly, that a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, may be used alone or in combination with aspirin after PTCA in the treatment of thromboembolic diseases of arterial origin. Although it is now known that anti-factor Xa pentasaccharides and aspirin act via two different mechanisms of action, the combination or the association of these active ingredients for use as antithrombotics has never been studied.
Thus, according to one of its aspects, the subject of the present invention is the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via AT III, alone or in combination with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty.
According to the invention, selective inhibitor of factor Xa is understood to mean a compound capable of selectively inhibiting factor Xa via antithrombin III but not possessing a significant activity towards thrombin.Preferably the selective inhibitor of factor Xa has no activity towards thrombin.
Advantageously, the said synthetic oligo-saccharides are pentasaccharides, such as those included in patents EP 84999 and US 5,378,829.
Particularly advantageous pentasaccharides are especially:
methyl 0-(2-deoxy-2-sulphoamino-6-O-sulpho-a-D-gluco-pyranosyl)-(1~4)-O-(~-D-glucopyranosyluronic acid)-(1~4)-0-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-a-D-glucopyranosyl)-(1~4)-0-(2-O-sulpho-a-L-idopyranosyl-uronic acid)-(1~4)-2-deoxy-2-sulphoamino-6-O-sulpho-a-D-glucopyranoside, in which the anion has the structure (A) HO ~ H ~ ~ O ~ OMe (A) s6,- s'o,. so,. ~so,. s6, and its pharmaceutically acceptable salts, especially its decasodium salt, known by its code name SR 90107A
or ORG 31540, described in Chemical Synthesis to Glycoaminoglycans, Supplement to Nature 1991, 350, 30-33, deslgnated hereinafter "PS".
Methyl 0-(3,4-di-O-methyl-2,6-di-O-sulpho-a-D-glucopyranosyl)-(1~4)-0-(3-O-methyl-2-O-sulpho-~-D-glucopyranosyluronic acid)-(1~4)-0-(2,3,6-tri-O-sulpho-a-D-glucopyranosyl-(1~4)-0-(3-O-methyl-2-O-sulpho-a-L-idopyranosyluronic acid)-(1~4)-2,3,6-tri-O-sulpho-a-D-glucopyranoside, in which the anion has the structure (B) MeO
so,- So~- SO~- 50,. So~
and its pharmaceutically acceptable salts, especially its dodecasodium salt described in US 5,378,829;
Methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-a-D-glucopyran-osyl)-(1~4)-0-(2,3-di-O-methyl-~-D-glucopyranosyluronic acid)-(1~4)-O-(2,3,6-tri-O-sulpho-~-D-glucopyranosyl)-(1~4)-0-(2,3-di-O-methyl-~-L-idopyranosyluronic acid)-(1~4)-2,3,6-tri-O-sulpho-~-D-glucopyranoside, in which the anion has the structure (C) M ~ O ~ OM- (C) So~. SO~- so,- 50,, and its pharmaceutically acceptable salts, especially its nonasodium salt, also described in US 5,378,829.
The use of the compound of formula (A), preferably in decasodium salt form (PS) corresponds to a preferred embodiment of the invention.
The decasodium salt of the compound of structure (A) (PS), as representative compound for use according to the present invention has been the subject of a pilot clinical study in patients undergoing a transluminal angioplasty of the coronaries. A single dose of 12 mg of PS via the intravenous route and 500 mg of aspirin, via the intravenous route, was administered to the patients. The results which were obtained show the therapeutic value of the PS/aspirin association in the prevention and treatment of acute thromboses following a percutaneous transluminal angioplasty.
To assess the antithrombotic activity 71 patients with stable angina (26), recent unstable angina (11) or recent myocardial infarction (34) with type A or B coronary lesions underwent PTCA with a single 12 mg PS i.v. bolus injection and 500 mg i.v.
aspirin. Angiography was repeated 24 h after PTCA. The endpoints were thrombus formation at PTCA sites and the thrombolysis in myocardial infarction (TIMI) flow in target vessel. ~eparin was not allowed before, during and within 24 h after PTCA. Acute thrombotic closure at dissected PTCA site occured in 1 patient and distal 2 1 q9642 embolization of a thrombus containing plaque in patient. Vessel patency was restored in both patients with intracoronary alteplase. Stents were required in ll patients (for dissection in 9, suboptimal result in 2) who were given 250 mg ticlopidine at the time of implantation. Average minimal luminal diameter was 0.90 + 0.50 mm before and 2.65 + 0.40 mm after PTCA
(reference diameter 2.95 _ 0.60 mm). At 24 h TIMI 3 flow without thrombus at PTCA site was observed in all 71 patients. No major bleeding occurred. Anti-Xa activity peaked 10 min. after PS bolus (1.20 + 0.29 U
anti-Xa/ml) and was maintained on average at 0. a 7 +
0.14 U anti-Xa/ml 2 hours after PS administration. The activated clothing time ACT remained unchanged.
Thrombin-antithrombin complexes levels (TAT) fell from 21.9 + 18.7 to 4.8 + 3.8 ug/l and prothrombin fragment 1+2 from 2.08 + 1.04 to 1.54 + 82 ng/ml 2 hours after PS injection.
Thus the use according to the invention of an oligosaccharide, alone or in combination with aspirin is beneficial in relation to pathological states in patients having undergone a percutaneous transluminal angioplasty.
It will be noted that the use of the oligosaccharide, alone or in association with aspirin according to the invention, does not increase the haemorrhagic risk.
For the treatment of the abovementioned diseases, the oligosaccharide and the aspirin are administered to mammals, including man, at daily doses of the oligosaccharide or of the aspirin, respectively, of 0.1 to 100 mg per kilo of bodyweight of the mammal to be treated.
In a human being, the dose may vary for each of the components from 1 to 1000 mg per day, according to the age of the subject to be treated or the type of treatment: prophylactic or curative. Preferably, the pentasaccharide is administered at doses of between 0.30 mg and 30 mg per patient and per day.
The aspirin may be formulated in a pharmaceutical composition according to methods well known to persons skilled in the art. The same applies for the oligosaccharide.
The association of the oligosaccharide and the aspirin may be formulated in pharmaceutical compositions which may be used via the oral or parenteral route, especially via the subcutaneous or intravenous route, mixed with conventional pharmaceutical exclpients.
These pharmaceutical compositions are preferably provided in the form of dosage units containing a predetermined quantity of active ingredients, such as for example from 0.1 to 50 mg of lS oligosaccharide or of aspirin, respectively, per dosage unit.
When at least two active ingredients are formulated in the same composition, it is necessary to ensure the compatibility of the different active substances. Thus the oligosaccharide is preferably used in the form of an addition salt, for example the sodium salt. Generally, indeed, the oligosaccharides in the form of their addition salts with pharmaceutically acceptable acids are not chemically incompatible with aspirin.
Thus, according to another of its aspects, the subject of the invention is a pharmaceutical composition for the treatment or prophylaxy of thromboembolic diseases in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed 3s with one or more pharmaceutically acceptable excipients.
These compositions are produced so as to be administrable via the digestive or parenteral route.
The pharmaceutical compositions of the invention are advantageously presented in various forms, such as for example injectable or oral solutions, sugar-coated tablets, plain tablets or gelatin capsules. The injectable solutions are the preferred pharmaceutical forms.
In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, transmucosal, local or rectal administration, the active ingredient may be administered in unit forms for administration, mixed with conventional pharmaceutical carriers, to animals and to human beings. The appropriate unit forms for administration comprise the oral forms such as tablets, gelatin capsules, powders, granules, microgranules and oral solutions or suspensions, the forms for sublingual and oral administration, the forms for subcutaneous, intramuscular, intravenous, intranasal or intraocular administration and the forms for rectal administration.
When a solid composition in tablet form is prepared, the principal active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic and the like. The tablets may be coated with sucrose or other appropriate materials or they may be treated so that they have a prolonged or delayed activity and continuously release a predetermined quantity of active ingredient.
A preparation in gelatin capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard gelatin capsules.
The water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or flavour correctors.
For a rectal administration, suppositories are used which are prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
s For a parenteral, intranasal or intraocular administration aqueous suspensions, isotonic saline solutions and sterile and injectable solutions are used which contain dispersing agents and/or wetting agents which are pharmacologically acceptable, for example propylene glycol or butylene glycol.
For a transmucosal administration, the active ingredients may be formulated in the presence of a promoter such as a bile salt, a hydrophilic polymer such as for example hydropropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethyl cellulose, carboxymethyl cellulose, dextran, polyvinylpyrrolidone, pectins, starches, gelatin, casein, acrylic acids, acrylic esters and copolymers thereof, vinyl polymers or copolymers, vinyl alcohols, alkoxy polymers, polyethylene oxide polymers, polyethers or a mixture thereof.
The active ingredients may also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
The active ingredients may also be provided in the form of a complex with a cyclodextrin, for example a- ~- or ~-cyclodextrin, 2-hydroxypropyl-~-cyclodextrin, or methyl-~-cyclodextrin.
One of the active ingredients, for example the oligosaccharide, may also be released by a balloon containing it or by an endovascular stent introduced into the blood vessels. The pharmacological efficacy of the active ingredient is thus not affected.
According to a preferred embodiment of the 3s invention, the pharmaceutical compositions comprise the association of aspirin and the compound of formula (A) preferably in the form of its decasodium salt.
Preferably still, the oligosaccharide is administered via the intravenous or subcutaneous route.
The pharmaceutical compositions of the invention contain, preferably, from 5 to 30 mg of an oligosaccharide which is a selective inhibitor of factor Xa and 200 to 800 mg of aspirin, better still from 8 to 20 mg of the said oligosaccharide and from 400 to 600 mg of aspirin, for example 12 mg of the said oligosaccharide and 500 mg of aspirin.
AN ANTI-Xa OLIGOSACCHARIDE AND USE OF AN ANTI-Xa OLIGOSACCHARIDE OPTIONALLY IN COM3INATION WITH ASPIRIN"
The subject of the present inventlon is the use of synthetic oligosaccharides with factor Xa inhibiting activity which act via antithrombin III, alone or in combination with aspirin, in the treatment of thromboembolic diseases which occur during or after a percutaneous transluminal angioplasty (PTCA).
Pharmaceutical compositions containing the combination of the active ingredients oligosaccharides and aspirin are also part of the invention.
The active ingredients which constitute the combination are present in the free state or in the form of one of their pharmacologically acceptable salts.
During the last decade, a wide interest has been shown in the study of the role played by platelets in the development of the thromboembolic diseases associated with arteriosclerosis (myocardial infarc-tion, angina, cerebral vascular accident, arterial diseases of the lower limbs and the li~e). Moreover, the well-established role of the blood coagulation process in arterial thrombosis has allowed the development of numerous medicaments which inhibit the various coagulation enzymes. The discovery of the essential role of thrombin and of factor Xa in the thrombotic process has led to the use of anticoagulants being proposed in the prevention and treatment of arterial thrombosis.
Among the available anticoagulants, heparin is the preferred medicament in the prevention and treatment of thromboembollc diseases.
~eparin catalyses, especially via antithrombin III (AT III), the inhibition of two enzymes which are la involved in the blood coagulation cascade, namely factor Xa and factor IIa (or thrombin). The relative importance of these two activities in the overall activity of heparin remains unknown. Low molecular weight heparin (LMWH) preparations contain chains formed of 4 to 30 monosaccharides which act like property of being more selective for factor Xa than thrombin. Despite this different biological activity profile, low molecular weight heparin has an antithrombotic effect as has been demonstrated in studies on animals and on patients suffering from thromboembolic diseases or exhibiting risks of formation of a thrombus (Hirsch J. et al, J. Thromb.
Hemost., 1987, Leuven, Belgium Leuven University Press, 325-348).
Unlike heparin and the LMWHs, some synthetic oligosaccharides, especially those described in EP
84999, have the property of selectively inhibiting factor Xa via antithrombin III but do not possess any activity on thrombin.
lS These synthetic oligosaccharides corresponding to the antithrombin binding domain (ABD) of heparin are known and manifest an antithrombotic activity in venous thrombosis. These compounds are described in EP 529715 and EP 621282 The efficacy of these oligosaccharides in the treatment of thromboembolic diseases occurring during or after percutaneous transluminal angioplasty was not very likely because of their incapacity to inhibit thrombin which is the mechanism involved in the thromboses resulting from a PTCA.
Indeed, it has long been known in the literature that thrombin plays a key role in arterial thrombosis and this is again confirmed by recent experiments (L. A. Harker, Blood, 1991, 77, 1006-1012). Thrombin inhibitors therefore constitute aneffective means for preventing and combating this type of thrombosis after PTCA.
It has been observed, by comparing the efficacy of heparin with those of direct thrombin inhibitors (a direct inhibitor is an inhibitor which inhibits thrombin without requiring AT III as intermediate), that the latter are a lot more effective than heparin for preventing and treating arterial thrombosis (Arteriosclerosis and thrombosis, 1992, 12, 879-885. J.
Am. Coll. Cardiol., 1994, 23, 993-1003). The probable reason for this lack of efficacy is that the heparin/AT
III complex cannot, for reasons to do with stearic hindrance, inhibit thrombin in a platelet-rich thrombus as is a platelet thrombus.
The weak heparin activity, compared to the direct inhibitors, is therefore linked to its need to use AT III.
A compound which, on the one hand, acts itself via AT III as intermediate, and, on the other hand, does not inhibit thrombin would therefore be expected to be ineffective in the treatment of arterial thromboses after percutaneous transluminal angioplasty.
It has now been found, according to the present invention, quite surprisingly, that a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, may be used alone or in combination with aspirin after PTCA in the treatment of thromboembolic diseases of arterial origin. Although it is now known that anti-factor Xa pentasaccharides and aspirin act via two different mechanisms of action, the combination or the association of these active ingredients for use as antithrombotics has never been studied.
Thus, according to one of its aspects, the subject of the present invention is the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via AT III, alone or in combination with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty.
According to the invention, selective inhibitor of factor Xa is understood to mean a compound capable of selectively inhibiting factor Xa via antithrombin III but not possessing a significant activity towards thrombin.Preferably the selective inhibitor of factor Xa has no activity towards thrombin.
Advantageously, the said synthetic oligo-saccharides are pentasaccharides, such as those included in patents EP 84999 and US 5,378,829.
Particularly advantageous pentasaccharides are especially:
methyl 0-(2-deoxy-2-sulphoamino-6-O-sulpho-a-D-gluco-pyranosyl)-(1~4)-O-(~-D-glucopyranosyluronic acid)-(1~4)-0-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho-a-D-glucopyranosyl)-(1~4)-0-(2-O-sulpho-a-L-idopyranosyl-uronic acid)-(1~4)-2-deoxy-2-sulphoamino-6-O-sulpho-a-D-glucopyranoside, in which the anion has the structure (A) HO ~ H ~ ~ O ~ OMe (A) s6,- s'o,. so,. ~so,. s6, and its pharmaceutically acceptable salts, especially its decasodium salt, known by its code name SR 90107A
or ORG 31540, described in Chemical Synthesis to Glycoaminoglycans, Supplement to Nature 1991, 350, 30-33, deslgnated hereinafter "PS".
Methyl 0-(3,4-di-O-methyl-2,6-di-O-sulpho-a-D-glucopyranosyl)-(1~4)-0-(3-O-methyl-2-O-sulpho-~-D-glucopyranosyluronic acid)-(1~4)-0-(2,3,6-tri-O-sulpho-a-D-glucopyranosyl-(1~4)-0-(3-O-methyl-2-O-sulpho-a-L-idopyranosyluronic acid)-(1~4)-2,3,6-tri-O-sulpho-a-D-glucopyranoside, in which the anion has the structure (B) MeO
so,- So~- SO~- 50,. So~
and its pharmaceutically acceptable salts, especially its dodecasodium salt described in US 5,378,829;
Methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-a-D-glucopyran-osyl)-(1~4)-0-(2,3-di-O-methyl-~-D-glucopyranosyluronic acid)-(1~4)-O-(2,3,6-tri-O-sulpho-~-D-glucopyranosyl)-(1~4)-0-(2,3-di-O-methyl-~-L-idopyranosyluronic acid)-(1~4)-2,3,6-tri-O-sulpho-~-D-glucopyranoside, in which the anion has the structure (C) M ~ O ~ OM- (C) So~. SO~- so,- 50,, and its pharmaceutically acceptable salts, especially its nonasodium salt, also described in US 5,378,829.
The use of the compound of formula (A), preferably in decasodium salt form (PS) corresponds to a preferred embodiment of the invention.
The decasodium salt of the compound of structure (A) (PS), as representative compound for use according to the present invention has been the subject of a pilot clinical study in patients undergoing a transluminal angioplasty of the coronaries. A single dose of 12 mg of PS via the intravenous route and 500 mg of aspirin, via the intravenous route, was administered to the patients. The results which were obtained show the therapeutic value of the PS/aspirin association in the prevention and treatment of acute thromboses following a percutaneous transluminal angioplasty.
To assess the antithrombotic activity 71 patients with stable angina (26), recent unstable angina (11) or recent myocardial infarction (34) with type A or B coronary lesions underwent PTCA with a single 12 mg PS i.v. bolus injection and 500 mg i.v.
aspirin. Angiography was repeated 24 h after PTCA. The endpoints were thrombus formation at PTCA sites and the thrombolysis in myocardial infarction (TIMI) flow in target vessel. ~eparin was not allowed before, during and within 24 h after PTCA. Acute thrombotic closure at dissected PTCA site occured in 1 patient and distal 2 1 q9642 embolization of a thrombus containing plaque in patient. Vessel patency was restored in both patients with intracoronary alteplase. Stents were required in ll patients (for dissection in 9, suboptimal result in 2) who were given 250 mg ticlopidine at the time of implantation. Average minimal luminal diameter was 0.90 + 0.50 mm before and 2.65 + 0.40 mm after PTCA
(reference diameter 2.95 _ 0.60 mm). At 24 h TIMI 3 flow without thrombus at PTCA site was observed in all 71 patients. No major bleeding occurred. Anti-Xa activity peaked 10 min. after PS bolus (1.20 + 0.29 U
anti-Xa/ml) and was maintained on average at 0. a 7 +
0.14 U anti-Xa/ml 2 hours after PS administration. The activated clothing time ACT remained unchanged.
Thrombin-antithrombin complexes levels (TAT) fell from 21.9 + 18.7 to 4.8 + 3.8 ug/l and prothrombin fragment 1+2 from 2.08 + 1.04 to 1.54 + 82 ng/ml 2 hours after PS injection.
Thus the use according to the invention of an oligosaccharide, alone or in combination with aspirin is beneficial in relation to pathological states in patients having undergone a percutaneous transluminal angioplasty.
It will be noted that the use of the oligosaccharide, alone or in association with aspirin according to the invention, does not increase the haemorrhagic risk.
For the treatment of the abovementioned diseases, the oligosaccharide and the aspirin are administered to mammals, including man, at daily doses of the oligosaccharide or of the aspirin, respectively, of 0.1 to 100 mg per kilo of bodyweight of the mammal to be treated.
In a human being, the dose may vary for each of the components from 1 to 1000 mg per day, according to the age of the subject to be treated or the type of treatment: prophylactic or curative. Preferably, the pentasaccharide is administered at doses of between 0.30 mg and 30 mg per patient and per day.
The aspirin may be formulated in a pharmaceutical composition according to methods well known to persons skilled in the art. The same applies for the oligosaccharide.
The association of the oligosaccharide and the aspirin may be formulated in pharmaceutical compositions which may be used via the oral or parenteral route, especially via the subcutaneous or intravenous route, mixed with conventional pharmaceutical exclpients.
These pharmaceutical compositions are preferably provided in the form of dosage units containing a predetermined quantity of active ingredients, such as for example from 0.1 to 50 mg of lS oligosaccharide or of aspirin, respectively, per dosage unit.
When at least two active ingredients are formulated in the same composition, it is necessary to ensure the compatibility of the different active substances. Thus the oligosaccharide is preferably used in the form of an addition salt, for example the sodium salt. Generally, indeed, the oligosaccharides in the form of their addition salts with pharmaceutically acceptable acids are not chemically incompatible with aspirin.
Thus, according to another of its aspects, the subject of the invention is a pharmaceutical composition for the treatment or prophylaxy of thromboembolic diseases in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed 3s with one or more pharmaceutically acceptable excipients.
These compositions are produced so as to be administrable via the digestive or parenteral route.
The pharmaceutical compositions of the invention are advantageously presented in various forms, such as for example injectable or oral solutions, sugar-coated tablets, plain tablets or gelatin capsules. The injectable solutions are the preferred pharmaceutical forms.
In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, transmucosal, local or rectal administration, the active ingredient may be administered in unit forms for administration, mixed with conventional pharmaceutical carriers, to animals and to human beings. The appropriate unit forms for administration comprise the oral forms such as tablets, gelatin capsules, powders, granules, microgranules and oral solutions or suspensions, the forms for sublingual and oral administration, the forms for subcutaneous, intramuscular, intravenous, intranasal or intraocular administration and the forms for rectal administration.
When a solid composition in tablet form is prepared, the principal active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic and the like. The tablets may be coated with sucrose or other appropriate materials or they may be treated so that they have a prolonged or delayed activity and continuously release a predetermined quantity of active ingredient.
A preparation in gelatin capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard gelatin capsules.
The water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or flavour correctors.
For a rectal administration, suppositories are used which are prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
s For a parenteral, intranasal or intraocular administration aqueous suspensions, isotonic saline solutions and sterile and injectable solutions are used which contain dispersing agents and/or wetting agents which are pharmacologically acceptable, for example propylene glycol or butylene glycol.
For a transmucosal administration, the active ingredients may be formulated in the presence of a promoter such as a bile salt, a hydrophilic polymer such as for example hydropropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethyl cellulose, carboxymethyl cellulose, dextran, polyvinylpyrrolidone, pectins, starches, gelatin, casein, acrylic acids, acrylic esters and copolymers thereof, vinyl polymers or copolymers, vinyl alcohols, alkoxy polymers, polyethylene oxide polymers, polyethers or a mixture thereof.
The active ingredients may also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
The active ingredients may also be provided in the form of a complex with a cyclodextrin, for example a- ~- or ~-cyclodextrin, 2-hydroxypropyl-~-cyclodextrin, or methyl-~-cyclodextrin.
One of the active ingredients, for example the oligosaccharide, may also be released by a balloon containing it or by an endovascular stent introduced into the blood vessels. The pharmacological efficacy of the active ingredient is thus not affected.
According to a preferred embodiment of the 3s invention, the pharmaceutical compositions comprise the association of aspirin and the compound of formula (A) preferably in the form of its decasodium salt.
Preferably still, the oligosaccharide is administered via the intravenous or subcutaneous route.
The pharmaceutical compositions of the invention contain, preferably, from 5 to 30 mg of an oligosaccharide which is a selective inhibitor of factor Xa and 200 to 800 mg of aspirin, better still from 8 to 20 mg of the said oligosaccharide and from 400 to 600 mg of aspirin, for example 12 mg of the said oligosaccharide and 500 mg of aspirin.
Claims (12)
1. A pharmaceutical composition for the treatment or prophylaxy of thromboembolic diseases in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin.
2. A pharmaceutical composition according to claim 1, comprising form 5 to 30 mg of the said oligosaccharide and from 200 to 800 mg of aspirin.
3. Composition according to claim 1, comprising from 8 to 20 mg of the said oligosaccharide and from 400 to 600 mg of aspirin.
4. A pharmaceutical composition according to claim 1, wherein the oligosaccharide is methyl 0-(2-deoxy-2-sulphoamino-6-0-sulpho-.alpha.-D-glucopyranosyl)-(1~4)-0-(.beta.-D-glucopyranosyluronic acid)-(1~4)-0-(2-deoxy-2-sulphoamino-3,6-di-0-sulpho-.alpha.-D-glucopyranosyl)-(1~4)-0-(2-0-sulpho-.alpha.-L-idopyranosyl-uronic acid)-(1~4)-2-deoxy-2-sulphoamino-6-0-sulpho-.alpha.-D-glucopyranoside, in which the anion has the structure (A) or one of its pharmaceutically acceptable salts.
5. A pharmaceutical composition according to claim 4, wherein the oligosaccharide is the decasodium salt.
6. A pharmaceutical composition according to claim 1 further comprising one or more pharmaceutically acceptable excipients.
7. Use of an effective quantity of at least one synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in combination with aspirin for the preparation of a medicine for the treatment or prophylaxy of thromboembolic diseases in a mammal having undergone a percutaneous transluminal angioplasty.
8. Use according to claim 7, in which the oligosaccharide is methyl 0-(2-deoxy-2-sulphoamino-6-0-sulpho-.alpha.-D-glucopyranosyl)-(1~4)-0-(.beta.-D-glucopyrano-syluronic acid)-(1~4)-0-(2-deoxy-2-sulphoamino-3,6-di-0-sulpho-.alpha.-D-glucopyranosyl)-(1~4)-0-(2-0-sulpho-.alpha.-L-idopyranosyluronic acid)-(1~4)-2-deoxy-2-sulphoamino-6-0-sulpho-.alpha.-D-glucopyranoside, in which the anion has the structure (A) or one of its pharmaceutically acceptable salts.
9. Use according to claim 8, in which the oligosaccharide is the decasodium salt.
10. Use according to claim 7, wherein the administration of the medicine implies the administration of 0.1 to 100 mg of oligosaccharide per day and per kilo of body weight of the mammal to be treated.
11. Use according to claim 10, wherein the treatment further comprises the administration of 0.1 to 100 mg of aspirin per day and per kilo of body weight of the mammal to be treated.
12. Use according to claim 7, characterized in that the medicine is administered via the intravenous or subcutaneous route.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002199642A CA2199642C (en) | 1997-03-10 | 1997-03-10 | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| EA199700025A EA000048B1 (en) | 1997-03-10 | 1997-03-13 | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of anti-xa oligosaccharide optionally in combination with aspirin |
| AU16319/97A AU698456B2 (en) | 1997-03-10 | 1997-03-14 | Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin |
| BR9701313A BR9701313A (en) | 1997-03-10 | 1997-03-17 | Compositions containing an association of aspririn and an anti-xa oligosaccharide and use of an anti-xa olysaccharide optionally in combination with aspirin |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002199642A CA2199642C (en) | 1997-03-10 | 1997-03-10 | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| AU16319/97A AU698456B2 (en) | 1997-03-10 | 1997-03-14 | Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin |
| BR9701313A BR9701313A (en) | 1997-03-10 | 1997-03-17 | Compositions containing an association of aspririn and an anti-xa oligosaccharide and use of an anti-xa olysaccharide optionally in combination with aspirin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2199642A1 CA2199642A1 (en) | 1998-09-10 |
| CA2199642C true CA2199642C (en) | 2001-05-08 |
Family
ID=27152254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002199642A Expired - Lifetime CA2199642C (en) | 1997-03-10 | 1997-03-10 | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU698456B2 (en) |
| BR (1) | BR9701313A (en) |
| CA (1) | CA2199642C (en) |
| EA (1) | EA000048B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| UA80399C2 (en) * | 2001-11-13 | 2007-09-25 | Glaxo Group Ltd | Use of specific dose of fondaparinux sodium for the treatment of acs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564468B1 (en) * | 1984-05-16 | 1994-12-23 | Choay Sa | NOVEL OLIGOSACCHARIDES, THEIR SYNTHESIS PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
| AU563351C (en) * | 1982-01-15 | 2003-06-19 | Glaxo Group Limited | Synthesis of oligosaccharides |
-
1997
- 1997-03-10 CA CA002199642A patent/CA2199642C/en not_active Expired - Lifetime
- 1997-03-13 EA EA199700025A patent/EA000048B1/en not_active IP Right Cessation
- 1997-03-14 AU AU16319/97A patent/AU698456B2/en not_active Expired
- 1997-03-17 BR BR9701313A patent/BR9701313A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU698456B2 (en) | 1998-10-29 |
| EA000048B1 (en) | 1998-04-30 |
| BR9701313A (en) | 1998-11-17 |
| CA2199642A1 (en) | 1998-09-10 |
| EA199700025A1 (en) | 1997-12-30 |
| AU1631997A (en) | 1998-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2184547C2 (en) | New combinations of klopidogrel-containing active agent and antithrombosis agent | |
| NO323739B1 (en) | Preparations for the Treatment and Prevention of Arterial Thrombosis and Use of a Factor Xa Inhibitor Combined with an Anti-Platelet Aggregate | |
| Herbert et al. | SR123781A, a synthetic heparin mimetic | |
| US20060040896A1 (en) | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity | |
| WO2001039781A1 (en) | Pharmaceutical combinations | |
| WO2000064470A1 (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug | |
| JP3813169B2 (en) | Antithrombotic | |
| Matsuo et al. | Development of argatroban, a direct thrombin inhibitor, and its clinical application | |
| Beijering et al. | Clinical applications of new antithrombotic agents | |
| CH661439A5 (en) | MODIFIED GLYCOSAMINOGLICANS EQUIPPED WITH ANTI-THROMBOTIC ACTIVITY. | |
| CA2199642C (en) | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin | |
| US20060122151A1 (en) | Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin | |
| JP3169343B2 (en) | Compositions containing a combination of aspirin and anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin | |
| MXPA97001943A (en) | Compositions containing an acetilsalicilic acid association and an anti-xa oligosacarid and use of an anti-xa oligosacaride optionally in combination with acetilsalicil acid | |
| KR100231978B1 (en) | Compositions containing an association of aspirin and anti-xa oligosaccharide optionally in combination with aspirin | |
| Niada et al. | Protective activity of defibrotide against lethal acute myocardial ischemia in the cat | |
| US20040214751A1 (en) | Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients | |
| AU2001291549A1 (en) | Antithrombotic compositions | |
| AU2002363023B2 (en) | A combination product comprising melagatran and dexamethasone | |
| AU707215B2 (en) | Thrombolytic agents | |
| Perianu | Clinical safety profile of cefodizime | |
| CA2293081A1 (en) | Restenosis drug therapy | |
| Lakhal et al. | MODIFICATION OF COAGULATION AND FIBRINOLYSIS DURING TRANSLUMINAL ANGIOPLASTY IN PATIENTS RECEIVING HEPARIN OR PENTOSAN POLYSULFATE (HEMOCLAR) | |
| ZA200108544B (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170310 |